J
Judith Hsia
Researcher at AstraZeneca
Publications - 163
Citations - 26695
Judith Hsia is an academic researcher from AstraZeneca. The author has contributed to research in topics: Women's Health Initiative & Estrogen. The author has an hindex of 58, co-authored 138 publications receiving 25272 citations. Previous affiliations of Judith Hsia include George Washington University & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
Garnet L. Anderson,Marian C. Limacher,Annlouise R. Assaf,Tamsen Bassford,Shirley A.A. Beresford,Henry R. Black,Denise E. Bonds,Robert L. Brunner,Robert G. Brzyski,Bette J. Caan,Rowan T. Chlebowski,J. David Curb,Margery Gass,Jennifer Hays,Gerardo Heiss,Susan L. Hendrix,Barbara V. Howard,Judith Hsia,F. Allan Hubbell,Rebecca D. Jackson,Karen C. Johnson,Howard L. Judd,Jane Morley Kotchen,Lewis H. Kuller,Andrea Z. LaCroix,Dorothy S. Lane,Robert Langer,Norman L. Lasser,Cora E. Lewis,JoAnn E. Manson,Karen L. Margolis,Judith K. Ockene,Mary Jo O'Sullivan,Lawrence S. Phillips,Ross L. Prentice,Cheryl Ritenbaugh,John A Robbins,Jacques E. Rossouw,Gloria E. Sarto,Marcia L. Stefanick,Linda Van Horn,Jean Wactawski-Wende,Robert B. Wallace,Sylvia Wassertheil-Smoller +43 more
TL;DR: The use of conjugated equine estrogen (CEE) increases the risk of stroke, decreases therisk of hip fracture, and does not affect CHD incidence in postmenopausal women with prior hysterectomy over an average of 6.8 years, indicating no overall benefit.
Journal ArticleDOI
Estrogen plus progestin and the risk of coronary heart disease
JoAnn E. Manson,Judith Hsia,Karen C. Johnson,Jacques E. Rossouw,Annlouise R. Assaf,Norman L. Lasser,Maurizio Trevisan,Henry R. Black,Susan R. Heckbert,Robert Detrano,Ora L. Strickland,Nathan D. Wong,John R. Crouse,Evan A. Stein,Mary Cushman +14 more
TL;DR: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use.
Journal ArticleDOI
Calcium plus vitamin D supplementation and the risk of fractures.
Rebecca D. Jackson,Andrea Z. LaCroix,Margery Gass,Robert B. Wallace,John A Robbins,Cora E. Lewis,Tamsen Bassford,Shirley A.A. Beresford,Henry R. Black,Patricia L. Blanchette,Denise E. Bonds,Robert L. Brunner,Robert G. Brzyski,Bette J. Caan,Jane A. Cauley,Rowan T. Chlebowski,Steven R. Cummings,Iris A. Granek,Jennifer Hays,Gerardo Heiss,Susan L. Hendrix,Barbara V. Howard,Judith Hsia,F. Allan Hubbell,Karen C. Johnson,Howard L. Judd,Jane Morley Kotchen,Lewis H. Kuller,Robert Langer,Norman L. Lasser,Marian C. Limacher,Shari E. Ludlam,JoAnn E. Manson,Karen L. Margolis,Joan McGowan,Judith K. Ockene,Mary Jo O'Sullivan,Lawrence S. Phillips,Ross L. Prentice,Gloria E. Sarto,Marcia L. Stefanick,Linda Van Horn,Jean Wactawski-Wende,Evelyn P Whitlock,Garnet L. Anderson,Annlouise R. Assaf,David H. Barad +46 more
TL;DR: Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones.
Journal ArticleDOI
Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials
JoAnn E. Manson,Rowan T. Chlebowski,Marcia L. Stefanick,Aaron K. Aragaki,Jacques E. Rossouw,Ross L. Prentice,Garnet L. Anderson,Barbara V. Howard,Cynthia A. Thomson,Andrea Z. LaCroix,Jean Wactawski-Wende,Rebecca D. Jackson,Marian C. Limacher,Karen L. Margolis,Sylvia Wassertheil-Smoller,Shirley A.A. Beresford,Jane A. Cauley,Charles B. Eaton,Margery Gass,Judith Hsia,Karen C. Johnson,Charles Kooperberg,Lewis H. Kuller,Cora E. Lewis,Simin Liu,Lisa W. Martin,Judith K. Ockene,Mary Jo O'Sullivan,Lynda H. Powell,Michael S. Simon,Linda Van Horn,Mara Z. Vitolins,Robert B. Wallace +32 more
TL;DR: Most risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up and the 2 WHI hormone therapy trials do not support use of this therapy.
Journal ArticleDOI
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
Eugene Braunwald,Michael J. Domanski,Sarah E. Fowler,Nancy L. Geller,Bernard J. Gersh,Judith Hsia,Marc A. Pfeffer,Madeline Murguia Rice,Yves Rosenberg,Jean L. Rouleau,Peace Investigators +10 more
TL;DR: In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization.